Based upon a successful engagement with the US Food and Drug Administration (FDA) at the End-of-Phase 2 meeting in January 2025, Atea is initiating a global Phase 3 program and expects patient ...

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for ...

UCB, a global biopharmaceutical company, today announced positive data from studies involving its investigational pyrimidine nucleoside therapy, doxecitine (dC) and doxribtimine (dT), in people living ...

In a case with implications for the litigious molecular diagnostics space and written description law, Chief Judge Connolly of the District of Delaware reversed a $96 million jury verdict in favor of ...

Scientists have tapped into the Summit supercomputer to study an elaborate molecular pathway called nucleotide excision ...

The Vietnam Hepatitis Treatment Market was valued at USD 146.25 million in 2023 and is projected to reach USD 197.35 million by 2029, growing at a CAGR of 5.08% during the forecast period. The ...

Using single-cell RNA sequencing, we mapped thousands of expression quantitative trait loci in yeast, including a variant in GPA1 that influences gene expression, cell-cycle occupancy, and mating ...